Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

6 results about "Multiplex" patented technology

In the biological sciences, a multiplex assay is a type of immunoassay that uses magnetic beads to simultaneously measure multiple analytes in a single experiment. A multiplex assay is a derivative of an ELISA using beads for binding the capture antibody. Multiplex assays are much more common in research than in clinical settings.

Method and kit for detecting Helicobacter pylori drug resistance gene mutations

ActiveCN111996273AImprove detection efficiencyReduce testing costsMicrobiological testing/measurementDNA/RNA fragmentationGenes mutationMultiplex
The invention provides a method and kit for detecting Helicobacter pylori drug resistance gene mutations. Specifically, the method detects drug resistance gene site mutations of five commonly used Helicobacter pylori antibiotics (including clarithromycin, metronidazole, quinolones, amoxicillin and tetracycline) based on multiplex PCR-Time-of-flight mass spectrometry, and matching primer and probecombinations and the kit are provided.
Owner:BEIJING JIANWEI MEDICAL LAB CO LTD +1

Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes

PendingUS20220137064A1Avoid artifactsOrganic chemistryMicrobiological testing/measurementMass spectrometry imagingPathology diagnosis
The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).
Owner:AMBERGEN

MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS

PendingCN114072678APreparing sample for investigationDisease diagnosisMultiplexPhysiology
The present technology relates to methods for diagnosing, monitoring the progression of, assessing the efficacy of treatment of, or assessing risk for development of a neurodegenerative disorder in a patient. These methods are based on determining the ratio of beta-amyloid 42 ("A beta42") to beta- amyloid 40 ("A beta40") in a body fluid sample collected from a patient who has or is suspected of having a neurodegenerative disorder, using an improved and highly sensitive multiplex protein assay that simultaneously detects A beta42 and A beta40.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products